Antimicrobial susceptibility trends among gram-positive and -negative clinical isolates collected between 2005 and 2012 in Mexico: results from the Tigecycline Evaluation and Surveillance Trial. Issue 1 (December 2015)

• Record Type: Journal Article
• Authors: Morfin-Otero, Rayo; Noriega, Eduardo; Dowzicky, Michael
• Is Part Of: Annals of clinical microbiology and antimicrobials. Volume 14:Issue 1(2015)
• Page Start: 1
• Page End: 14
• Publication Date: 2015-12
• Subjects: Tigecycline -- Antimicrobial resistance -- Mexico -- Surveillance; Medical microbiology -- Periodicals; Anti-infective agents -- Periodicals; 616.9041
• DOI: 10.1186/s12941-015-0116-y
• Languages: English
• ISSNs: 1476-0711

Abstract

Abstract Background The Tigecycline Evaluation and Surveillance Trial (T.E.S.T) is a global antimicrobial surveillance study of both gram-positive and gram-negative organisms. This report presents data on antimicrobial susceptibility among organisms collected in Mexico between 2005 and 2012 as part of T.E.S.T., and compares rates between 2005–2007 and 2008–2012. Method Each center in Mexico submitted at least 200 isolates per collection year; including 65 gram-positive isolates and 135 gram-negative isolates. Minimum inhibitory concentrations (MICs) were determined using Clinical Laboratory Standards Institute (CLSI) broth microdilution methodology and antimicrobial susceptibility was established using the 2013 CLSI-approved breakpoints. For tigecycline US Food and Drug Administration (FDA) breakpoints were applied. Isolates ofE. coli andK. pneumoniae with a MIC for ceftriaxone of >1 mg/L were screened for ESBL production using the phenotypic confirmatory disk test according to CLSI guidelines. Results The rates of some key resistant phenotypes changed during this study: vancomycin resistance amongEnterococcus faecium decreased from 28.6 % in 2005–2007 to 19.1 % in 2008–2012, while β-lactamase production amongHaemophilus influenzae decreased from 37.6 to 18.9 %. Conversely, methicillin-resistantStaphylococcus aureus increased from 38.1 to 47.9 %, meropenem-resistantAcinetobacter spp. increased from 17.7 to 33.0 % and multidrug-resistantAcinetobacter spp. increased from 25.6 to 49.7 %. The prevalence of other resistant pathogens was stable over the study period, including extended-spectrum β-lactamase-positiveEscherichia coli (39.0 %) andKlebsiella pneumoniae (25.0 %). The activity of tigecycline was maintained across the study years with MIC90 s of ≤2 mg/L againstEnterococcus spp., S. aureus, Streptococcus agalactiae, Streptococcus pneumoniae, Enterobacter spp., E. coli, K. pneumoniae, Klebsiella oxytoca, Serratia marcescens, H. influenzae, andAcinetobacter spp. All gram-positive organisms were susceptible to tigecycline and susceptibility among gram-negatives ranged from 95.0 % forK. pneumoniae to 99.7 % forE. coli . Conclusion Antimicrobial resistance continues to be high in Mexico. Tigecycline was active against gram-positive and gram-negative organisms, including resistant phenotypes, collected during the study.